AXA Investment Managers’s Charles River Laboratories CRL Stock Holding History

AXA Investment Managers’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.1M	Buy	+7,039	New	+$1.12M	﹤0.01%	879

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AXA Investment Managers's CRL Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Charles River Laboratories (CRL) in Q3 2025: 7,039 shares worth $1.1M. The stake represents ﹤0.01% of the portfolio and ranks #879 among its holdings.

554 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

AXA Investment Managers held 7,039 shares of Charles River Laboratories worth $1.1M as of Q3 2025.
Charles River Laboratories was a new AXA Investment Managers position in Q3 2025.
Charles River Laboratories made up ﹤0.01% of AXA Investment Managers's portfolio in Q3 2025, its #879 holding.
554 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.